Media

Oncopeptides – COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Intervacc – Report from Annual General Meeting

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Intervacc – Interim report January – March 2026

Intervacc strengthens management team for future growth

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

Vicore Pharma Elects Peter Guenter to its Board of Directors

Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Pharma – Interim Report January – March 2026

Oncopeptides – Invitation to presentation of the Q1 report 2026